OptimizeRx reports Q1 non-GAAP EPS 8c, consensus (12c)

Reports Q1 revenue $21.9M, consensus $18.69M. Cash, cash equivalents and short-term investments totaled $16.6M as of March 31, as compared to $13.4M as of December 31, 2024. Stephen Silvestro, CEO, commented, “I’m encouraged by our year-to-date performance, which has exceeded both consensus estimates and our internal expectations. The momentum we saw at the end of 2024 has carried into 2025, with year-to-date contracted revenue up more than 20% compared to the same period last year-positioning us well for a strong second half of the year. I believe this performance clearly reflects the results of our focus on operational excellence, our commitment to delighting customers, and our efforts to deepen relationships with valued business partners, all of which are driving meaningful shareholder value. At the same time, we’ve already converted over 5% of our expected 2025 sales into subscription-based revenue streams. I believe this transition, combined with our improving operating leverage, puts us on a strong path toward achieving Rule of 40 performance in the coming years.”